Dr Lal PathLabs

January 30, 2025

National Stock Exchange of India Limited Exchange Plaza, Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051

Symbol: LALPATHLAB

BSE Limited Corporate Relationship Department Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400 001

Scrip Code: 539524

Sub: <u>Earnings Presentation on Un-audited Financial Results (Standalone and</u> <u>Consolidated) for the Quarter and Nine Months ended December 31, 2024</u>

Dear Sir/Madam,

Please find attached a copy of Company's Q3 & 9M FY25 Earnings Presentation, which the Company proposes to share with Analysts / Investors with respect to its Un-audited Financial Results (Standalone and Consolidated) for the Quarter and nine months ended December 31, 2024, as approved by the Board of Directors in their meeting held on January 30, 2025.

We request you to please take the same on record.

Thanking You, Yours Faithfully,

For Dr. Lal PathLabs Limited

Vinay Gujral Company Secretary & Compliance Officer


Encl.: As above

8 Dr Lal PathLabs

Dr. Lal PathLabs Limited (DLPL)

Q3 & 9M FY25 Results Presentation

January 2025



Disclaimer

By attending the meeting / telephonic call where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations:

The information in this presentation has been prepared by Dr Lal PathLabs Limited (the "Company") for use in presentations by the Company at analyst and investor meetings and does not constitute a recommendation regarding the securities of the Company. No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information, or opinions contained herein. Neither the Company nor any of its advisors or representatives shall have any responsibility or liability whatsoever (for negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with this presentation. The information set out herein may be subject to updating, completion, revision, verification and amendment and such information may change materially. Neither the Company nor any of its advisors or representatives is under any obligation to update or keep current the information contained herein. The information communicated in this presentation contains certain statements that are or may be forward looking. These statements typically contain words such as "will", "expects" and "anticipates" and words of similar import. By their nature forward looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. Any investment in securities issued by the Company will also involve certain risks. There may be additional material risks that are currently not considered to be material or of which the Company and its advisors or representatives are unaware. Against the background of these uncertainties, readers should not unduly rely on these forward-looking statements. The Company, its advisors and representatives assume no responsibility to update forward-looking statements.

This presentation has been prepared for informational purposes only. This presentation does not constitute a prospectus under the (Indian) Companies Act, 2013 and will not be registered with any registrar of companies. Furthermore, this presentation is not and should not be construed as an offer or a solicitation of an offer to buy securities for sale in the India. This presentation and the information contained herein does not constitute or form part of any offer for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities of the Company, nor should it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The securities of the Company have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered, sold or delivered within the United States or to U.S. persons absent from registration under or an applicable exemption from the registration requirements of the United States securities laws. This presentation and the information contained herein is being furnished to you solely for your information and may not be reproduced or redistributed to any other person, in whole or in part. In particular, neither the information contained in this presentation, nor any copy hereof may be, directly or indirectly, taken or transmitted into or distributed in the U.S., Canada, Australia, Japan or any other jurisdiction which prohibits the same except in compliance with applicable securities laws. Any failure to comply with this restriction may constitute a violation of the United States or other national securities laws. No money, securities or other consideration is being solicited, and, if sent in response to this presentation or the information contained herein, will not be accepted.

By reviewing this presentation, you are deemed to have represented and agreed that you and any person you represent are either (a) a qualified institutional buyer (within the meaning of Regulation 144A under the Securities Act) or (b) not a U.S. person (as defined in Regulation S under the Securities Act) and are outside of the United States and not acting for the account or benefit of a U.S. person.


Table of Contents

DLPL - At a Glance	4
Q3 FY25 Performance Overview	5
Financials	6
Key Performance Highlights	7
Management Commentary	10
Corporate Overview	11
Shareholding	27
Contact Us	29

DISCLAIMER: This presentation may contain 'forward-looking' statements at places. The Company's business operations remain subject to undetermined contingencies and risks. Dr. Lal PathLabs Limited would not be liable for any action undertaken based on such 'forward-looking' statements and does not commit to revising/updating 3 them publicly.

2 Dr Lal PathLabs

Dr. Lal PathLabs – At a Glance



Dr Lal PathLabs

As on March 31, 2024 *Largest on the basis of revenue and presence

Test count has been rationalized basis current practice

Q3 FY25 Performance Overview

	Q3 FY25		Q3 FY24
10.7%	Rs. 597 crore	Revenue	Rs. 539 crore
9.6%	Rs. 154 crore	EBITDA	Rs. 141 crore
19.3%	Rs. 98 crore	PAT	Rs. 82 crore
10.3%	20.6 Mn	Samples	18.6 Mn
3.8%	6.9 Mn	Patients SwasthFit	6.7 Mn
+3%	23%	Contribution	20%



Financials


Particulars (Rs. Cr.)	Q3 FY25	Q3 FY24	Gr %	YTD Dec'24	YTD Dec'23	Gr %
Revenue	597	539	10.7%	1,859	1,681	10.6%
Operating Expenditure	443	398		1,332	1,217	
EBITDA	154	141	<i>9.6%</i>	527	465	13.3%
Margins	25.8%	26.1%		28.3%	27.6%	
Other Income	25	18		68	51	
Depreciation	36	36		106	107	
EBIT	144	123	<i>16.8%</i>	489	408	19.6%
Margins	24.1%	22.8%		26.3%	24.3%	
Finance Cost	5	7		17	23	
PBT	138	116	19.4%	471	386	22.2%
Margins	23.2%	21.5%		25.4%	22.9%	
PAT	98	82	<i>19.3%</i>	337	277	21.8%
Margins	16.4%	15.3%		18.1%	16.4%	
EPS (Basic)	11.6	9.8		39.9	32.9	




Key performance highlights

- Revenue of Rs. 597 crore in Q3 FY25, a growth of 10.7% Y-o-Y; 9M FY25 revenue of Rs. 1859 crore, an increase of 10.6% Y-o-Y
 - Volume-led growth achieved through deeper penetration in core markets and calibrated expansion in newer regions of West & South
 - West region contributed 15% to the total revenue in Q3 FY25
- Growing sample and patient volumes are driving increased operating leverage, enabling the Company to maintain competitive pricing while realising efficiency gains through optimized IT infrastructure. Active business mix management further enhanced profitability this year
 - For 9M FY25, EBITDA growth by 13.3% Y-o-Y
- Update on Suburban Diagnostics
 - Consistent near double-digit growth continues. Revenue growth of 9.2% and 9.8% in Q3 FY25 & 9M FY25 respectively

Operating Highlights



Increasing DLPL reach in Tier 3+



Management Commentary

Commenting on the performance, (Hony) Brig. Dr. Arvind Lal, Executive Chairman said:

"I am pleased that we continue to strengthen our leadership in the Indian diagnostics space, driven by our focus on accuracy, quality, and accessibility. The need to strengthen primary and secondary healthcare infrastructure, especially in rural areas and in cities classified as Tier 3, and beyond, has never been more pressing. With increasing prevalence of noncommunicable diseases, the role of organized diagnostics in delivering timely and reliable testing is becoming critical.

Our national footprint, now at ${\sim}280$ labs and ${\sim}5,700$ collection centers, is expanding deeper into Tier III and beyond.

Investments in digital infrastructure, AI and genomics are enhancing efficiency and early diagnosis. This is also equipping us to meet evolving patient needs. Our operations continue to scale up according to our pre-defined strategy, backed by over 75 years of experience. As a leader in healthcare, it is our goal to provide quality care to everyone in the country.

Commenting on the performance, Dr. Om Manchanda, Managing Director said:

"We continue to drive growth through strategic expansion and deeper market penetration. While we have not taken any price hikes in nearly 2 years, sample growth is fueled by higher testing per patient and the strong momentum of SwasthFit, particularly in underserved towns and cities.

Our franchise network is expanding, with each lab now servicing a larger number of collection centers. In North and East India, our cluster-based approach is accelerating growth in Tier 3 & 4 cities, while in the West, Suburban Diagnostics is gaining traction. In South and West India, we are also strengthening infrastructure and brand communication to boost sample volumes.

We are focusing investments in frontline capabilities to enhance B2B outcomes. With a strong brand, growing bundled offerings, and a commitment to accessibility, we are well-positioned for sustained growth and leadership in the industry."

(Hony) Brig. Dr. Arvind Lal, Executive Chairman



Dr. Om Manchanda, Managing Director



Mr. Shankha Banerjee, Chief Executive Officer


Commenting on the performance, Mr. Shankha Banerjee, Chief Executive Officer said:

"We delivered strong financial results in the third quarter of fiscal year 2025, with 10.7% revenue growth and 19.3% increase in profit after tax. Our focus on operational excellence, coupled with proactive initiatives on visibility and brand, contributed significantly to enhanced profitability while maintaining competitive pricing. Sample volumes grew by 10.3% Y-o-Y, with a patient growth of 3.8%.

We are accelerating our reach with the planned opening of 15-20 new labs in this financial year. We are expanding our reach into Tier 3 and Tier 4 markets while strengthening our presence in the Core regions. We are making investments in new infrastructure in Metro / Tier 1 cities as well. Our focus on innovation, including new bundled test packages and the expansion of high-end and superspecialty tests, will continue to drive growth and enhance patient experience. Our robust digital infrastructure will play a crucial role in supporting this growth by providing seamless access and personalized solutions."



Corporate Overview




Overview of Dr. Lal PathLabs

Established brand	Established consumer healthcare brand in diagnostic services	
Pan-India integrated coverage	280 clinical labs (including National Reference Lab at Delhi and Regional Reference labs at Kolkata, Bangalore & Mumbai), 5,762 Patient Service Centers (PSCs) and 11,619 Pick-up Points (PUPs)	Well-positioned in one of the fastest-growing
Varied Offerings	Catalogue of 343 test panels, 3,075 pathology tests and 1,439 radiology and cardiology tests	segments of the Indian healthcare industry
Unique and successful operating model	Scalable model integrated through centralised IT platform allows for network expansion	

ABDM - All Milestones acheived, DLPL among early adopters

Ayushman Bharat Digital Mission aims to create a National Digital Health Ecosystem to bridge the existing gap amongst different stakeholders of Healthcare ecosystem through digital highways. The mission also enables interoperability and portability of health records and support innovation and research in the health sector.




The benefits of the mission are manifold and will help the entire ecosystem, from Policy Makers to Researchers, and Health Care Professionals to Patients.

Vision, Mission & Values

Be the most trusted healthcare partner, enabling healthier lives

To be an undisputed market leader by providing accessible, affordable, timely and quality healthcare, diagnostics, applying insights and cutting-edge technology to create value for all stakeholders




DLPL Strategy for future growth

Significantly leverage the strong digital infrastructure

- Deployed AI, data analytics, machine learning tools to elevate the patient experience & offer customized solutions
- Dedicated digital team in place to amplify the volume trajectory

Enhance high-end test portfolio of super-specialty & bundled test

- Created specialty verticals like Genevolve to focus on genomics, L-CoRD to focus on reproductive diagnostics, and L-ACE to focus on auto-immune disorders.
- 'Swasthfit' remains at the core, to offer comprehensive bundled solutions to patients



Drive higher volumes in high-potential markets of Western & Southern India and hub labs in rest of north

- Follow cluster city approach to steer growth in key pockets
- Enhance presence in Maharashtra especially Mumbai through Suburban Diagnostics
- Launched Reference labs in Bengaluru & Mumbai

Leveraging digital infrastructure to make life easier for patient

New Website Launch

- New age user intuitive website.
- Responsive, mobile friendly web designs. .
- SEO friendly for improved customer reach ٠
- Strategic placement of Buttons and Web forms to . generate more leads and better order conversion rates from website

Reco.ai

- LPL's own AI based Recommendation Engine ٠
- Recommends Patient relevant tests as per ٠ his current health condition, past report trends, demographic details, etc.

Logistics App

- Machine Learning based FE Route Generation .
- Machine Learning based Tube Scanning Bag creation process.
- Secure QR Code based handshake for every process. .
- Geo-fencing and Precious sample recognition ٠ Intra and Intercity sample movement.



Wallet

- Senior Citizen Wallet: Wallet points on every booking for Senior Citizen Patients.
- Phlebo Wallet: Wallet points on enhanced ٠ superior services to customers.

One Registration


- One unified platform for all POS registrations
- Error Proofing ٠

Chatbot 2.0

- New version of Chatbot. ٠
- Book an appointment functionality. ٠
- ETR and Report visibility of customer orders. ٠ **Recommendation of Preventive Health** Checkups




Summary highlights – Technical Lab Operations



17 S Dr Lal PathLab

Genevolve: Genetic Testing Division



18 2 Dr Lal PathLabs

Highest Quality Standards in the Industry

Best in the Industry CAP Proficiency Testing Score at 97.5% for National Reference Lab

Consistently high EQAS Performance Testing Score at 98.3% for Satellite Labs

CAP accreditation 2 labs, NABL accreditation 37 Labs

partners

Real time quality control monitoring


100+ Quality **Risk based** improvement meetings on a quality daily basis with assurance the network framework

Digitally enabled solutions implemented for quality audits and trainings




Patent has been granted to Dr. Lal PathLabs for an invention related to **REAL TIME QUALITY** CONTROL **MONITORING** for the period of 20 years

Quality Control





Enhanced Customer Experience in Home Collection



CSR Projects

LPL Foundation's flagship program of vocational training focuses on Skilling and Comprehensive School Health Program

1. Skilling: LPL Academy for Laboratory Medicine - Phlebotomist Training

Impact Assessment Metrics (Key findings from survey of sample size)

45% of respondents surveyed were BPL (below the poverty line) candidates.

51% joined the program due to high placement record and 49% due to program certification by authorized bodies and schemes like NSDC and Skill India.

59% of participants' salary expectations were met.

100% of participants completed OJT and found the program to be Good and Very Good.


99% of participants responded that they were guided enough during OJT through guidance, feedback, monitoring and follow-ups by the training centre Representatives.

92% of respondents were provided options from multiple employers indicating placement efficiency.

92-93% of respondents reported positive impact in personality, confidence and soft skills.

91-93% provided positive feedback on course content and training implementation.

92% were able to contribute to savings and household expenses indicating a positive impact on quality of life.






Key ESG Initiatives



Savings of >1.3 million aliquots and >5,210 tons of plastic waste in our lab – a strong commitment to sustainability

Dr. Lal Pathlabs' leadership vision focuses on continuous improvement while maintaining best-in-class patient services. Furthermore, we are strongly committed to optimizing our laboratory's environmental footprint.


We reduced the need for aliquots by 93% by replacing our previous system configuration^{1,2} with new, innovative automation, analyzers, and IT solutions. Reduced use of plastic for aliquots optimizes waste management and significantly reduces CO² emissions.



^{1.} Siemens Healthineers automation and IT solution vs. the previous system configuration from Roche Diagnostics, Abbott Diagnostics, and Beckman Coulter Diagnostics.

- 2. Case study: Dr. Lal Pathlabs harnesses the power of digitalization. Published by Siemens Healthcare Diagnostics Inc. · Order No. 30-22-DX-1342-76 · 08-2022 · © Siemens Healthcare Diagnostics Inc., 20222.
- 3. ZWE_Policy-briefing_The-impact-of-Waste-to-Energy-incineration-on-Climate.pdf
- Theoretical worldwide average using the epa.gov/energy/greenhouse-gases-equivalencies-calculator
- 5. Expected financial savings for the contract duration, depending on test mix and market pricing during this time period.

Cyber Security Capability



Experienced Management team



(Hony.) Brig. Dr. Arvind Lal Executive Chairman



Ved Prakash Goel Group Chief Financial Officer &

CEO – International Business



Dr. Om Manchanda Managing Director



Munender Soperna Chief Information Officer



Dr. Vandana Lal Whole-time Director



Jai Prakash Meena Chief Operating Officer




Shankha Banerjee Chief Executive Officer



Manoj Garg Group Chief Human Resources Officer



Shareholding as of 31st December, 2024



Key Awards & Recognition



Contact Us

About Dr. Lal PathLabs Limited (DLPL)

Dr. Lal PathLabs Limited is one of India's leading consumer healthcare brand in diagnostic services.

It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. The services of DLPL are aimed at individual patients, hospitals and other healthcare providers and corporates. The catalogue of services includes 343 test panels, 3,075 pathology tests and 1,439 radiology and cardiology tests as on March 31, 2024.

As on March 31, 2024, DLPL's has 280 clinical labs (including National Reference Lab at Delhi & Regional Reference Lab at Kolkata, Bangalore & Mumbai), 5,762 Patient Service Centers (PSCs) and 11,619 Pick-up Points (PUPs). In FY23 & FY24, DLPL collected and processed approximately 72 million samples and 78 million samples from 26.9 million and 27.6 million patients, respectively.

Additional information on Dr. Lal PathLabs Limited: Corporate Identification No: L74899DL1995PLC065388

Website: https://www.lalpathlabs.com

	Ved Goel	Siddharth Rangnekar / Nishid Solanki
The family an	Dr. Lal PathLabs Limited	CDR India
For further information	Tel: +91 124 301 6500	Tel: +91 22 66451209 / 1221
please contact:	Fax: +91 124 423 4468	Fax: +91 22 66451213
	E-mail: ved.goel@lalpathlabs.com	Email: siddharth@cdr-india.com / nishid@cdr-india.com

